 Home > Active Ingredient News > Immunology News > Rheumatology: Effects of population-based cognitive behavioral therapy on insomnia in patients with rheumatoid arthritis, a randomized controlled trial

Rheumatology: Effects of population-based cognitive behavioral therapy on insomnia in patients with rheumatoid arthritis, a randomized controlled trial

 Last Update: 2022-08-19
 Source: Internet
 Author: User

Tags

meloxicam rheumatoid arthritis

secondary tubing

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

OBJECTIVE: The primary objective was to compare the effects of cognitive-behavioral therapy for insomnia (CBT-I) with usual care on sleep efficiency, as measured by polysomnography (PSG) immediately after the intervention at week 7. Secondary objectives were to compare the long-term effects of week 26 on sleep and rheumatoid arthritis (RA)-related outcome.

Methods: In a randomized controlled trial with a parallel-group design, the experimental intervention was a 6-week nurse-guided group-based CBT-.

RESULTS: The ITT population included 62 patients (89% female) with a mean age of 58 years and a mean sleep efficiency of 81.

For the primary endpoint, sleep efficiency was 87% in the CBT-I group compared with 87% in the control group at PSG measurement at week 7 [difference: 03 (95% CI -37 to -143); p = 068.

There was no improvement in key secondary outcomes measured using PSG at week 26.

There were statistically highly significant differences between CBT-I and usual care for all patient-reported key secondary sleep and RA-related outcomes (p

CONCLUSIONS: Nurse-guided group CBT-I did not affect sleep efficiency as objectively measured by PS.

Source:

Latocha KM, Løppenthin KB, Østergaard M, et a.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.